New insights into pneumococcal disease

Respirology

Volumn 14, Issue 2, 2009, Pages 167-179

  Feldman, Charles ^a,b,c   Anderson, Ronald ^d,e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

Antibiotic therapy; Community acquired pneumonia; Immunization; Pathogenesis; Pneumolysin; Streptococcus pneumoniae

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BINDING PROTEIN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CHOLINE BINDING PROTEIN; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; GEMIFLOXACIN; HYALURONIDASE; LEVOFLOXACIN; MACROLIDE; MEMBRANE PROTEIN; METAL BINDING PROTEIN; METALLOPROTEINASE; MOXIFLOXACIN; PENICILLIN G; PNEUMOCOCCAL SURFACE PROTEIN; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIALIDASE; UNCLASSIFIED DRUG; ZINC METALLOPROTEINASE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BACTERIAL VIRULENCE; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCURRENT INFECTION; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG ANTAGONISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFECTION RISK; LOW DRUG DOSE; MENINGITIS; NONHUMAN; OTITIS MEDIA; PANBRONCHIOLITIS; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SMOKING;

EID: 61349125517     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01422.x     Document Type: Review

References (145)

1. Feldman C, Anderson R. Controversies in the treatment of pneumococcal community-acquired pneumonia. Future Microbiol. 2006 1 : 271 81.
2. Farr BM, Woodhead MA, MacFarlane JT, Bartlett CLR, McCracken JS et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir. Med. 2000 94 : 422 7.
3. Farr BM, Bartlett CLR, Wadsworth J, Miller DL, in association with members of the British Thoracic Society Pneumonia Study Group. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. Respir. Med. 2000 94 : 954 63.
4. Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I et al., and the Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur. Respir. J. 2008 31 : 1274 84.
5. Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC et al. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch. Intern. Med. 2000 160 : 3082 8.
6. Almirall J, Gonzalez CA, Balanzo X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999 116 : 375 9.
7. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur. Respir. J. 1999 13 : 349 55.
8. Fernandez-Sola J, Junque A, Estruch R, Monforte R, Torres A et al. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch. Intern. Med. 1995 155 : 1649 54.
9. Feldman C. The role of alcohol in severe pneumonia and acute lung injury. In : Rello J, Leeper K Jr. (eds) Severe Community Acquired Pneumonia. Kluwer Academic Publishers, Boston, MA, 2001 139 52.
10. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A et al. Cigarette smoking and invasive pneumococcal disease. N. Engl. J. Med. 2000 342 : 681 9.
11. Jover F, Cuadrado J-M, Andreu L, Martinez S, Canizares R et al. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur. J. Intern. Med. 2008 19 : 15 21.
12. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch. Intern. Med. 2004 164 : 2206 16.
13. Raman AS, Swinburne AJ, Fedullo AJ. Pneumococcal adherence to the buccal epithelial cells of cigarette smokers. Chest 1983 83 : 23 7.
14. Greenberg D, Givon-Lavi N, Broides A, Blancovich I, Peled N et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin. Infect. Dis. 2006 42 : 897 903.
15. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N. Engl. J. Med. 2008 333 : 845 51.
16. Madeddu G, Porqueddu EM, Cambosu F, Saba F, Fois AG et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008 36 : 231 6.
17. Feldman C, Glatthaar M, Morar R, Goolam Mahomed A, Kaka S et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest 1999 116 : 107 14.
18. Gill CJ, Mwanakasale V, Fox MP, Chilengi R, Tembo M et al. Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women. J. Infect. Dis. 2008 197 : 1000 5.
19. Buie KA, Klugman KP, von Gottberg A, Perovic O, Karstaedt A et al. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. J. Infect. Dis. 2004 189 : 1996 2000.
20. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J. Gen. Intern. Med. 2005 20 : 1142 5.
21. Miguez-Burbano MJ, Burbano X, Ashkin D, Pitchenik A, Allan R et al. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict. Biol. 2003 8 : 39 43.
22. Feldman C, Klugman KP, Yu VL, Ortqvist A, Choiu CCC et al. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J. Infect. 2007 55 : 125 35.
23. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Med. 2008 6 : 288 301.
24. Preston JA, Dockrell DH. Virulence factors in pneumococcal respiratory pathogenesis. Future Microbiol. 2008 3 : 205 21.
25. Feldman C, Munro N, Jeffery PF, Mitchell TJ, Andrew PW et al. Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am. J. Respir. Cell Mol. Biol. 1991 5 : 416 23.
26. Feldman C, Anderson R, Cockeran R, Mitchell TJ, Cole P et al. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro. Respir. Med. 2002 96 : 580 5.
27. Feldman C, Cockeran R, Jedrzejas MJ, Mitchell TJ, Anderson R. Hyaluronidase augments pneumolysin-mediated injury to human ciliated respiratory epithelium. Int. J. Infect. Dis. 2007 11 : 11 5.
28. Wani J, Gilbert J, Plaut A, Weiser J. Identification, cloning and sequencing of the immunoglobulin A1 protease gene of Streptococcus pneumoniae. Infect. Immun. 1996 64 : 3967 74.
29. Dave S, Carmicle S, Hammerschmidt S, Pangburn M, McDonald L. Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J. Immunol. 2004 173 : 471 77.
30. Soong G, Muir A, Gomez MI, Waks J, Reddy B et al. Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. J. Clin. Invest. 2006 116 : 2297 305.
31. Allegrucci M, Sauer K. Characterization of colony morphology variants isolated from Streptococcus pneumoniae biofilms. J. Bacteriol. 2007 189 : 2030 8.
32. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit. Care Med. 2006 34 : 1947 54.
33. Hirst R, Mohammed B, Mitchell TJ, Andrew PW, O'Callaghan C. Streptococcus pneumoniae-induced inhibition of rat ependymal cells is attenuated by anti-pneumolysin antibody. Infect. Immun. 2004 72 : 6694 8.
34. Hirst RA, Kadioglu A, O'Callaghan C, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin. Exp. Immunol. 2004 138 : 195 201.
35. Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 2004 4 : 144 54.
36. Ogunniyi AD, Grabowicz M, Briles D, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 2007 75 : 350 7.
37. Ratner AJ, Hippe KR, Aguilar JL, Bender MH, Nelson AL et al. Epithelial cells are sensitive detectors of bacterial pore-forming toxins. J. Biol. Chem. 2006 281 : 12994 8.
38. Koga T, Lim JH, Jono H, Ha UH, Xu H et al. Tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signalling. J. Biol. Chem. 2008 283 : 12 546 54.
39. Mathias KA, Roche AM, Standish AJ, Shchepetov M, Weiser JN. Neutrophil-toxin interactions promote antigen delivery and mucosal clearance of Streptococcus pneumoniae. J. Immunol. 2008 180 : 6246 54.
40. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. USA 2003 100 : 1966 71.
41. MacLeod H, Wetzler LM. T cell activation by TLRs: a role for TLRs in the adaptive immune response. Sci. STKE 2007 2007 : pe48.
42. Dessing MC, Florquin S, Paton JC, van der Poll T. Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci. Cell. Microbiol. 2008 10 : 237 46.
43. + T cells more susceptible to productive infection with X4 and R5 HIV-Type 1. J. Immunol. 2007 179 : 4357 66.
44. Imanishi T, Haran H, Suzuki S, Suzuki N, Akira S et al. Cutting edge: TLR2 directly triggers Th1 effector functions. J. Immunol. 2007 178 : 6715 9.
45. + T cells. J. Immunol. 2005 175 : 1551 7.
46. Xu D, Komai-Koma M, Liew FY. Expression and function of Toll-like receptor on T cells. Cell. Immunol. 2005 233 : 85 9.
47. Kadioglu A, Coward W, Colston M, Hewitt C, Andrew PW. CD4 T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 2004 72 : 2689 97.
48. + T cells mediate antibody-independent immunity to pneumococcal colonization. Proc. Natl. Acad. Sci. USA 2005 102 : 4848 53.
49. + T-cell-dependent protection against pneumococal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect. Immun. 2007 75 : 5460 4.
50. + T cells. Infect. Immun. 2008 76 : 2678 84.
51. Raveh D, Kruskal BA, Farland J, Ezekowitz RAB. Th1 and Th2 cytokines cooperate to stimulate mannose-receptor-mediated phagocytosis. J. Leukoc. Biol. 1998 64 : 108 13.
52. Sun K, Salmon SL, Lotz SA, Metzger DW. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect. Immun. 2007 75 : 1196 202.
53. Zamze S, Martinez-Pomares L, Jones H, Taylor PR, Stillion RJ et al. Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the macrophage mannose receptor. J. Biol. Chem. 2002 277 : 41613 23.
54. Kang YS, Kim JY, Bruening SA, Pack M, Charalambous A et al. The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide of Streptococcus pneumoniae in the marginal zone of the mouse spleen. Proc. Natl. Acad. Sci. USA 2004 101 : 215 20.
55. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defence by interferon-gamma during recovery from influenza infection. Nat. Med. 2008 14 : 558 64.
56. Cockeran R, Anderson R, Feldman C. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch. Immunol. Ther. Exp. 2005 3 : 189 98.
57. Garcia-Suarez Mdel M, Florez N, Astudillo A, Vazquez F, Villaverde R. The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model. Respir. Res. 2007 8 : 3.
58. Martner A, Dahlgren C, Paton JC, Wold AE. Pneumolysin released during Streptococcus pneumoniae autolysis is a potent activator of intracellular oxygen radical production in neutrophils. Infect. Immun. 2008 76 : 4079 87.
59. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J. Lab. Clin. Med. 2004 143 : 269 83.
60. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr. Opin. Infect. Dis. 2002 15 : 163 7.
61. Fuller JD, McGreer A, Low DE. Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 : 780 8.
62. Finch RG, Remington JS. Global White Paper on bacterial resistance in community-acquired respiratory tract infections. Clin. Microbiol. Infect. 2002 8 : 1 128.
63. Lujan M, Gallego M, Rello J. Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med. 2006 32 : 971 80.
64. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus Pneumoniae to β-lactam antibiotics. Arch. Intern. Med. 2001 161 : 2538 44.
65. Crnich CJ, Proctor RA. Treatment of pneumococcal pneumonia: what's in an MIC? Crit. Care Med. 2004 32 : 876 8.
66. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J. Antimicrob. Chemother. 2002 49 : 433 6.
67. Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J et al., for the International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 2003 37 : 230 7.
68. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin. Infect. Dis. 2006 42 : 224 33.
69. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? Clin. Infect. Dis. 2006 42 : 234 7.
70. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg. Infect. Dis. 2005 11 : 802 6.
71. Rzeszutek M, Wierzbowski A, Hoban DJ, Conly J, Bishai W et al. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Int. J. Antimicrob. Agents 2004 24 : 95 104.
72. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J. Antimicrob. Chemother. 2002 50 : 87 91.
73. Nuermberger E, Bishai WR. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative. Clin. Infect. Dis. 2004 38 : 99 103.
74. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 2005 41 : 118 21.
75. Ambrose PG, Bast D, Doern GV, Iannini PB, Jones RN et al. Fluoroquinolone-resistant Streptococcus pneumoniae, an emerging but unrecognized public health concern: is it time to resight the goalposts? Clin. Infect. Dis. 2004 39 : 1554 7.
76. de Cueto M, Rodriguez JM, Soriano MJ, Lopez-Cerero L, Venero J et al. Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a pre-existing parC mutation. J. Clin. Microbiol. 2008 46 : 1558 60.
77. Waterer GW. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr. Opin. Infect. Dis. 2005 18 : 157 63.
78. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am. J. Med 1999 107 : S34 43.
79. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 2001 161 : 1837 42.
80. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 2003 36 : 389 95.
81. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A et al., and the International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 2004 170 : 440 4.
82. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can. Respir. J. 2004 11 : 589 93.
83. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999 159 : 2562 72.
84. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western States: 1993, 1995, and 1997. Chest 2001 119 : 1420 6.
85. Dudas V, Hopefl A, Jacobs R, Gugliemo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann. Pharmacother. 2000 34 : 446 52.
86. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003 123 : 1503 11.
87. Calzada SR, Tomas RM, Romero MJC, Moragon EM, Cataluna JJS et al. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission. Respir. Med. 2007 101 : 1909 15.
88. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 2007 51 : 3977 82.
89. Rodriguez A, Mendia A, Sirvent J-M, Barcenilla F, de la Torre-Prados MV et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit. Care Med. 2007 35 : 1493 99.
90. Dwyer R, Ortqvist A, Aufwerber E, Normark BH, Marrie TJ et al. Addition of a macrolide to a β-lactam in bacteremic pneumococcal pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2006 25 : 518 21.
91. Chokshi R, Restrepo MI Weeratunge N, Frei CR, Anzueto A et al. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 2007 26 : 447 51.
92. Harbarth S, Garbino J, Pugin J, Romand JA, Pittet D. Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 : 688 90.
93. Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur. Respir. J. 2007 30 : 525 31.
94. Aspa J, Rajas O, Rodriguez de Castro F, Huertas MC, Borderias L et al., on behalf of The Pneumococcal Pneumonia in Spain Study Group. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur. Respir. J. 2006 27 : 1010 19.
95. Lin TY, Lin SM, Chen HC, Wang CJ, Wang YM et al. An open-label, randomized comparison of levofloxacin and amoxycillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia. Chang Gung Med. J. 2007 30 : 321 32.
96. Finch R, Schurmann D, Collins O, Kubin R, McGivern J et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 2003 46 : 1746 54.
97. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P, and the MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis. 2005 41 : 1697 705.
98. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality of patients hospitalized with severe pneumonia. Crit. Care 2006 10 : R8 doi:10.1186/cc3934).
99. Waterer GW. Optimal antibiotic treatment in severe pneumococcal pneumonia - time for real answers. Eur. J. Clin. Microbiol. Infect. Dis. 2005 24 : 691 2.
100. Mills GD, Oehley MR, Arrol B. Effectiveness of β-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005 330 : 456 60.
101. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia. Arch. Intern. Med. 2005 165 : 1992 2000.
102. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst. Rev. 2008 1 : CD004418. DOI:10.1002/14651858.CD004418.pub3.
103. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia. Improved outcomes with macrolides but not fluoroquinolones. Chest 2007 131 : 466 73.
104. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J. Antimicrob. Chemother. 2000 46 : 973 80.
105. Mufson MA, Stanek RJ. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin. Infect. Dis. 2006 46 : 304 6.
106. Lagrou K, Peetermans WA, Jorrisen M, Verhagen J, Van Damme J et al. Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J. Antimicrob. Chemother. 2000 46 : 17 23.
107. Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakate Y et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur. Respir. J. 2006 27 : 1020 5.
108. Anderson R, Steel HC, Cockeran R, Smith AM, von Gottberg A et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J. Antimicrob. Chemother. 2007 59 : 224 9.
109. Feldman C, Anderson R. Non-antimicrobial activity of macrolides. Clin. Drug Investig. 2007 27 (Special Issue 1 27 35.
110. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. Curr. Infect. Dis. Rep. 2007 9 : 7 13.
111. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. Curr. Opin. Pulm. Med. 2006 12 : 440 4.
112. Keicho N, Kudoh S. Diffuse panbrochiolitis: role of macrolides in therapy. Am. J. Respir. Med. 2003 97 : 844 50.
113. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am. J. Resp. Crit. Care Med. 2008 177 : 148 55.
114. Verleden GM, Vanaudenaerde BM, Du Pont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 2006 174 : 566 70.
115. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996 20 : 693 705.
116. Sanz MJ, Nabah YN, Cerda-Nicolas M, O'Connor JE, Issekutz AC et al. Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression. Br. J. Pharmacol. 2005 144 : 190 201.
117. Vanaudenaerde BM, Wuyts WA, Geudens N, Du Pont LJ, Schoofs K et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from airway smooth muscle cells. Am. J. Transplant. 2007 7 : 76 82.
118. Shinkai M, Tamaoki J, Kobayashi H, Kanoh S, Motoyoshi K et al. Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays growth via extracellular signal-regulated protein kinase suppression. Antimicrob. Agents Chemother. 2006 50 : 1738 44.
119. Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 2006 350 : 977 82.
120. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J. Antimicrob. Chemother. 2005 55 : 10 21.
121. Giamarellos-Bourboulis EJ, Pechere JC, Routsi C, Plachouras D, Kollias S et al. Effect of clarithromycin on patients with sepsis and ventilator- associated pneumonia. Clin. Infect. Dis. 2008 46 : 1157 64.
122. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 2007 119 : 1055 62.
123. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM et al. Decline in invasive pneumococcal disease after the introduction of protein- polysaccharide conjugate vaccine. N. Engl. J. Med. 2003 348 : 1737 46.
124. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N et al., for the Vaccine Trialists Group. Trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 2003 349 : 1341 8.
125. Musher DM. Pneumococcal vaccine - direct and indirect ('Herd') effects. N. Engl. J. Med. 2006 354 : 1522 4.
126. Tasslimi A, Wenger P, Pentakota SR, Brimacombe M, Burday M et al. Invasive pneumococcal disease in an underimmunized, high HIV prevalence population. J. Infect. 2008 56 : 99 102.
127. Morbidity and Mortality Weekly Review. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR 2008 57 : 144 8.
128. Kellner J, Scheifele D, Vanderkooi OG, MacDonald J, Church DL et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr. Infect. Dis. J. 2008 27 : 526 32.
129. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 2007 196 : 1211 20.
130. Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 2008 27 : 519 25.
131. Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005 365 : 855 63.
132. Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis. 2007 195 : 347 52.
133. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W et al., for the Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV 7 vaccination, 1998-2004. J. Infect. Dis. 2007 196 : 1346 54.
134. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 2008 14 : 101 7.
135. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007 297 : 1784 92.
136. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J. 2007 26 : 123 8.
137. Park SY, Moore MR, Bruden DL, Hyde TB, Reasonover AL et al. Impact of conjugate vaccine on transmission of antimicrobial resistant Streptococcus pneumoniae among Alaskan children. Pediatr. Infect. Dis. J. 2008 27 : 335 40.
138. Beall B. Vaccination with the pneumococcal 7-valent conjugate: a successful experiment but the species is adapting. Expert Rev. Vaccines 2007 6 : 297 301.
139. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2007 26 : 468 72.
140. Bender JM, Ampofo K, Korgenski K, Daly J, Pavia AT et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin. Infect. Dis. 2008 46 : 1346 52.
141. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 2008 46 : 174 82.
142. Pelton SI. Replacement pneumococcal disease in perspective. Clin. Infect. Dis. 2008 46 : 1353 5.
143. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin. Infect. Dis. 2008 46 : 183 5.
144. Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A et al., for the Active Bacterial surveillance/Emerging Infections Program Network. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin. Infect. Dis. 2005 41 : 481 7.
145. Niederman MS. Recent advances in community-acquired pneumonia. Inpatient and outpatient. Chest 2007 131 : 1205 15.